Development of a BoHV-4 viral vector expressing tgD of BoHV-1 and evaluation of its immunogenicity in mouse model
Authors
Bilge-Dagalp, SevalFarzani, Touraj Aligholipour
Dogan, Firat
Akkutay Yoldar, Zeynep
Ozkul, Aykut
Alkan, Feray
Donofrio, Gaetano
UMass Chan Affiliations
Department of Molecular, Cell and Cancer BiologyDocument Type
Journal ArticlePublication Date
2021-07-13Keywords
Bovine herpesvirus 1Bovine herpesvirus 4
Immune response
TgD
Viral vector
Amino Acids, Peptides, and Proteins
Animal Experimentation and Research
Environmental Public Health
Genetic Phenomena
Genetics and Genomics
Therapeutics
Viruses
Metadata
Show full item recordAbstract
In recent years, Bovine herpesvirus 4 (BoHV-4) has emerged as an attractive gene delivery viral vector, mainly for vaccination purposes in the veterinary field. In the present study, a new infectious clone of the BoHV-4 genome carrying a bacterial artificial chromosome vector (BoHV-4-BAC) was developed by homologous recombination in mammalian cell culture and bacterial systems, and exploited to express a truncated form of glycoprotein D (tgD) of Bovine herpesvirus 1 (BoHV-1) (BoHV-4-tgDTK) as a vaccine candidate. This construct's immunogenicity was compared to a DNA vector expressing the same antigen (pC-tgD) in a BALB/c mouse model. After the mice were immunized, total and specific antibody responses, cytokine responses, total splenocyte cells proliferation/cytotoxicity, and virus neutralization assays were conducted to analyze the immune response elicited by both constructs. Mice from both vaccine groups developed significant humoral and cellular immune responses after a booster dose regime was conducted on day 28 post-injection. In almost all immunological assays, BoHV-4-tgDDeltaTK induced as high an immune response as pC-tgD. In both vaccine constructs, neutralizing antibodies were a significant determining factor in protection against BoHV-1, even after the first injection. We conclude that a BoHV-4-based viral vector offers an effective immunization strategy as an alternative to DNA-based immunization platforms, at least to combat BoHV-1.Source
Bilge-Dagalp S, Farzani TA, Dogan F, Akkutay Yoldar Z, Ozkul A, Alkan F, Donofrio G. Development of a BoHV-4 viral vector expressing tgD of BoHV-1 and evaluation of its immunogenicity in mouse model. Braz J Microbiol. 2021 Sep;52(3):1119-1133. doi: 10.1007/s42770-021-00525-z. Epub 2021 Jul 13. PMID: 34255309; PMCID: PMC8275906. Link to article on publisher's siteDOI
10.1007/s42770-021-00525-zPermanent Link to this Item
http://hdl.handle.net/20.500.14038/42682PubMed ID
34255309Related Resources
ae974a485f413a2113503eed53cd6c53
10.1007/s42770-021-00525-z